CASI Pharmaceuticals, Inc.

CASI

KYG1933S1012

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:30:01 31/05/2024 BST			5-day change	1st Jan Change
3.864 ^USD	+11.68%		+8.97%	-46.03%

05-15	Sector Update: Health Care Stocks Advance in Afternoon Trading	MT
05-15	CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study	MT

CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug Application for CID-103 in Immune Thrombocytopenia

May 15, 2024 at 01:00 pm

CASI Pharmaceuticals, Inc. announced the following: On April 12, 2024 CASI submitted the IND application to the FDA for CID-103 to support a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP). On May 13, 2024 CASI received a letter from FDA indicating that study may proceed. CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique.

Latest news about CASI Pharmaceuticals, Inc.

Sector Update: Health Care Stocks Advance in Afternoon Trading	05-15	MT
CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study	05-15	MT
CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug Application for CID-103 in Immune Thrombocytopenia	05-15	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q1 Revenue $3.4M, vs. Street Est of $12M	05-14	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Top Midday Gainers	03-05	MT
Looming Employment Report, Powell Testimony Stifle US Equity Futures Pre-Bell	03-05	MT
Rate Cut Uncertainty Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	03-05	MT
Top Premarket Gainers	03-05	MT
CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China	03-05	CI
CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals Co. Ltd Enter into Certain Agreement with Respect to the Renewal of the Exclusive Distribution Agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd	02-29	CI
Casi Pharmaceuticals Announces First Dose of Folotyn in China	02-16	CI
CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer	02-12	CI
CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer	01-30	CI
CASI Pharmaceuticals, Inc. Enters into an Exclusive Distribution Agreement with China National Medicines Corporation Ltd	12-08	CI
HC Wainwright Raises Price Target on CASI Pharmaceuticals to $12 From $10, Keeps Buy Rating	11-15	MT
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q3 Revenue $8.8M	11-14	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q2 Revenue $9.8M	11/08/23	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
CASI Pharmaceuticals Acquires Intellectual Property Rights to Cleave Therapeutics' Drug Candidate CB-5339	20/07/23	MT
CASI Pharmaceuticals, Inc.(NasdaqCM:CASI) dropped from S&P TMI Index	20/06/23	CI
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	17/05/23	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q1 Revenue $8.3M	17/05/23	MT

Chart CASI Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Companyâs Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for CASI Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.864 USD

Average target price

6 USD

Spread / Average Target

+55.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CASI PHARMACEUTICALS, INC.	-46.03%	50.19M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B

Other Pharmaceuticals

CASI Pharmaceuticals, Inc.

Equities

CASI

KYG1933S1012

Pharmaceuticals

CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug Application for CID-103 in Immune Thrombocytopenia

EPS Revisions